There has been a huge boom in the CBD market over the last few years with a plethora of new CBD products hitting the marketplace. From CBD brownies, to CBD coffee and even CBD sports gels, forecasters predict that the CBD industry will be worth nearly $2.5billion by 2027.
But as we explored in our recent blog post exploring CBD and pregnancy, there is not a great amount of research being done on women and the effects of CBD. If more and more people are using CBD as a natural pain relief, it follows that women experiencing period pains and menopausal symptoms might look to use a natural substance such as CBD to ease these symptoms. So we heartily welcome the news that a groundbreaking new trial is set to examine the potential of cannabis in women’s health products such as vaginal suppositories, lubricating gel and other women’s health products that contain cannabinoids.
Israeli medical cannabis firm Tikun Olam-Cannbit has signed a partnership agreement with Gynica to launch this ‘first of its kind’ clinical trial in the hope of developing a cannabinoid-based treatment for endometriosis, dysmenorrhea (menstrual pain) and dyspareunia (painful intercourse), and the trial is already showing promising results. The clinical study will be led by Professor Moshe Hod, a renowned international gynaecology expert and Professor of Obstetrics and Gynecology at the Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Avinoam Sapir, CEO of Tikun Olam-Cannbit, said, “We differentiate ourselves by not sufficing with inflorescence and oils, but strive for precise pharmaceutical formulations, with a precise indication that have been proven clinically effective through research. This is a market with a very strong potential, with markets such as Canada, Australia and the UK, which have a growing demand for these products and regulation that makes it possible”
We await the findings with anticipation.
Stay abreast of developments of this and other breaking CBD news stories in the CBD News section of the website.